611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Cancer
Resources
Basic InformationLatest News
Screening Often Misses Endometrial Cancer in Black WomenLong Distance to Care Can Mean Worse Outcomes for Young Cancer PatientsAlcohol Tied to 740,000 Cancer Cases Worldwide in 2020Cancer Survivors Fared Better Financially After ObamacarePandemic Delays in Screening Mean More Breast Cancer Deaths Ahead: StudyObese Men May Have Better Survival With Advanced Prostate CancerMost Cancer Screenings Make Big Rebound After Pandemic DeclineAdding MRI to Screening Can Cut Prostate Cancer Overdiagnosis in HalfU.S. Deaths From Cancer Continue to DeclineAlmost All Cancer Patients Respond Well to COVID-19 VaccinesCould Too Many Antibiotics Raise Your Odds for Colon Cancer?Too Little Sunlight, Vitamin D May Raise Colon Cancer RiskShining a Light on SunscreensGap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by EnoughCost a Barrier to Cervical Cancer Screening for Many U.S. WomenMost Americans Don't Follow Diets That Could Prevent CancerAHA News: Women With Heart Failure From Breast Cancer Treatment May Fare Better Than Previously ThoughtWomen's Cancer Screenings Plummeted During PandemicYoung Cancer Survivors Vulnerable to COVID, But Often Shun VaccineSome Myeloma Patients Get No Protection From COVID-19 VaccinesBlack Men Less Likely to Get Best Prostate Cancer TreatmentsCould Home Test for Colon Cancer Mean a Big Medical Bill to Come?Heart Failure Patients May Be at Higher Cancer RiskCould a DNA Blood Test Spot a Range of Hidden Cancers?For People With Heart Failure, Statins May Lower Cancer Risk TooMany 'High-Risk' Americans Unconcerned About Skin Cancer: PollSurvivors' Plasma Helps Blood Cancer Patients Battle COVID-19Race Doesn't Affect Risk for Genes That Raise Breast Cancer RiskHealthy Levels of Vitamin D May Boost Breast Cancer OutcomesStudy Pinpoints Cancer Patients at Highest Risk From COVIDCan You Keep Your Bladder After Bladder Cancer Strikes?Breast Cancer's Spread Is More Likely in Black Women, Study FindsNewly Approved Drug Fights Lung Cancer Tied to Certain GenesDrug Lynparza Could Help Fight Some Early-Stage Breast CancersTargeted Radiotherapy Might Help Men Battling Advanced Prostate CancerOut-of-Pocket Costs Delay Cancer Follow-Up Care, Even for the InsuredDon't Delay Lung Cancer Surgery, Study SuggestsModerate Use of Hair Relaxers Won't Raise Black Women's Cancer Risk: StudyFaulty Gene Could Raise Vulnerability to Asbestos-Linked CancerColonoscopy After 75: A Potential Lifesaver for MostBreast Cancer Treatments Don't Raise COVID RisksImmunotherapy Drug Can Beat Back Early-Stage Lung CancerKey Factors That Raise Your Odds for Early-Onset Colon CancerHPV Vaccination Is Lowering U.S. Cervical Cancer RatesAs Medicaid Access Expands, So Does Cancer SurvivalMS May Not Affect Breast Cancer PrognosisGet First Colonoscopy at 45, not 50: U.S. Expert PanelMelanoma Can Strike Your Nails: Here's How to CheckGene-Targeted Drug Shows Promise Against a Form of Pancreatic CancerObesity Raises Odds for Many Common Cancers
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

FDA Approves First AI Tool to Boost Colonoscopy Accuracy

HealthDay News
by Robert Preidt
Updated: Apr 13th 2021

new article illustration

TUESDAY, April 13, 2021 (HealthDay News) --The first device that uses artificial intelligence (AI) to help detect possible signs of colon cancer during colonoscopy has been approved by the U.S. Food and Drug Administration.

The GI Genius uses AI-based machine learning to help identify lesions such as polyps or suspected tumors in real time during a colonoscopy, according to the agency.

"Artificial intelligence has the potential to transform health care to better assist health care providers and improve patient care. When AI is combined with traditional screenings or surveillance methods, it could help find problems early on, when they may be easier to treat," said Courtney Lias, acting director of the GastroRenal, ObGyn, General Hospital and Urology Devices Office in the FDA's Center for Devices and Radiological Health.

She noted that studies show missed lesions during colon cancer screenings can be a problem even for well-trained clinicians.

"With the FDA's authorization of this device ..., clinicians now have a tool that could help improve their ability to detect gastrointestinal lesions they may have missed otherwise," she added in an agency news release.

The FDA's recent approval of the device is based on an Italian study that included 700 people between the ages of 40 and 80 who had colonoscopies with or without the use of GI Genius.

Colonoscopy plus GI Genius identified lab-confirmed adenomas or carcinomas in 55.1% of patients, compared to 42% with standard colonoscopy, according to the FDA.

The device includes hardware and software that highlights areas of the colon where a potential lesion is detected. During a colonoscopy, the software uses AI algorithm techniques to identify areas that may require further assessment, including closer visual inspection, tissue sampling, testing or removal, or ablation (burning) of the lesion.

The GI Genius is compatible with many standard video endoscopy systems.

Colon cancer is the third-leading cause of cancer death in the United States, according to the National Institutes of Health. Colon cancer usually starts from polyps or other precancerous growths.

Colonoscopies are performed as part of a colon cancer screening plan to detect changes or abnormalities in the lining of the colon and rectum.

More information

The American College of Surgeons has more on colonoscopy.


SOURCE: U.S. Food and Drug Administration, news release, April 9, 2021